DPP4 and congestive heart failure: The ongoing Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), designed to test the hypothesis that sitagliptin added to usual diabetes care does not increase CV risk in patients with existing CVD (estimated mean trial duration, approximately 4 years) [33], will also provide an evaluation of DPP-4 inhibitor therapy over a longer period than SAVOR-TIMI 53 or EXAMINE, and should provide additional information on the CHF issue.